Literature DB >> 33840834

Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3.

Cassis Varlow1,2, Andrew V Mossine3, Vadim Bernard-Gauthier1, Peter J H Scott3, Neil Vasdev1,2.   

Abstract

Glycogen synthase kinase 3 (GSK-3) is an enzyme that is dysregulated in oncology neurodegeneration, neuroinflammation and several mental health illnesses. As such, GSK-3 is a long-sought after target for positron emission tomography (PET) imaging and therapeutic intervention. Herein, we report on the development and radiofluorination of two oxazole-4-carboxamides, including one bearing a non-activated aromatic ring. Both compounds demonstrated excellent selectivity in a kinase screen and inhibit GSK-3 with high affinity. [18F]OCM-49 was synthesized from [18F]fluoride using a copper-mediated reaction of an aryl boronic acid precursor, while [18F]OCM-50 used a trimethylammonium triflate precursor, and both radiotracers were translated for preclinical PET imaging in rodents. Due to superior radiochemical yields and brain uptake (peak standardized uptake value of ~2.0), [18F]OCM-50 was further evaluated in non-human primate and also showed good brain uptake and rapid clearance. Further studies to consider clinical translation of both radiotracers are underway.

Entities:  

Keywords:  GSK-3; PET imaging; copper-mediated radiofluorination; fluorine-18; glycogen synthase kinase 3; neuroimaging

Year:  2021        PMID: 33840834      PMCID: PMC8034590          DOI: 10.1016/j.jfluchem.2021.109760

Source DB:  PubMed          Journal:  J Fluor Chem        ISSN: 0022-1139            Impact factor:   2.050


  32 in total

Review 1.  Pharmacological inhibitors of glycogen synthase kinase 3.

Authors:  Laurent Meijer; Marc Flajolet; Paul Greengard
Journal:  Trends Pharmacol Sci       Date:  2004-09       Impact factor: 14.819

2.  Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3.

Authors:  Lei Li; Xia Shao; Erin L Cole; Stephan A Ohnmacht; Valentina Ferrari; Young T Hong; David J Williamson; Tim D Fryer; Carole A Quesada; Phillip Sherman; Patrick J Riss; Peter J H Scott; Franklin I Aigbirhio
Journal:  ACS Med Chem Lett       Date:  2015-03-10       Impact factor: 4.345

3.  Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.

Authors:  Vadim Bernard-Gauthier; Andrew V Mossine; Ashley Knight; Debasis Patnaik; Wen-Ning Zhao; Chialin Cheng; Hema S Krishnan; Lucius L Xuan; Peter S Chindavong; Surya A Reis; Jinshan Michael Chen; Xia Shao; Jenelle Stauff; Janna Arteaga; Phillip Sherman; Nicolas Salem; David Bonsall; Brenda Amaral; Cassis Varlow; Lisa Wells; Laurent Martarello; Shil Patel; Steven H Liang; Ravi G Kurumbail; Stephen J Haggarty; Peter J H Scott; Neil Vasdev
Journal:  J Med Chem       Date:  2019-10-21       Impact factor: 7.446

4.  Late-stage [18F]Fluorination: New Solutions to Old Problems.

Authors:  Allen F Brooks; Joseph J Topczewski; Naoko Ichiishi; Melanie S Sanford; Peter J H Scott
Journal:  Chem Sci       Date:  2014-12-01       Impact factor: 9.825

Review 5.  Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation.

Authors:  D Arciniegas; L Adler; J Topkoff; E Cawthra; C M Filley; M Reite
Journal:  Brain Inj       Date:  1999-01       Impact factor: 2.311

Review 6.  Inhibition of Glycogen Synthase Kinase-3: An Emerging Target in the Treatment of Traumatic Brain Injury.

Authors:  Seong S Shim; Grace E Stutzmann
Journal:  J Neurotrauma       Date:  2016-05-09       Impact factor: 5.269

7.  Synthesis of Diverse (11)C-Labeled PET Radiotracers via Direct Incorporation of [(11)C]CO2.

Authors:  Andrew V Mossine; Allen F Brooks; Isaac M Jackson; Carole A Quesada; Phillip Sherman; Erin L Cole; David J Donnelly; Peter J H Scott; Xia Shao
Journal:  Bioconjug Chem       Date:  2016-04-14       Impact factor: 4.774

8.  Copper-Mediated Late-stage Radiofluorination: Five Years of Impact on Pre-clinical and Clinical PET Imaging.

Authors:  Jay S Wright; Tanpreet Kaur; Sean Preshlock; Sean S Tanzey; Wade P Winton; Liam S Sharninghausen; Nicholas Wiesner; Allen F Brooks; Melanie S Sanford; Peter J H Scott
Journal:  Clin Transl Imaging       Date:  2020-05-26

Review 9.  Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Authors:  Mukesh K Pandey; Timothy R DeGrado
Journal:  Theranostics       Date:  2016-02-17       Impact factor: 11.556

10.  Synthesis of [18F]Arenes via the Copper-Mediated [18F]Fluorination of Boronic Acids.

Authors:  Andrew V Mossine; Allen F Brooks; Katarina J Makaravage; Jason M Miller; Naoko Ichiishi; Melanie S Sanford; Peter J H Scott
Journal:  Org Lett       Date:  2015-11-14       Impact factor: 6.005

View more
  4 in total

1.  PET imaging of glycogen synthase kinase-3 in pancreatic cancer xenograft mouse models.

Authors:  Amanda J Boyle; Andrea Narvaez; Melissa Chassé; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2022-02-15

2.  In Vitro and In Vivo Evaluation of GSK-3 Radioligands in Alzheimer's Disease: Preliminary Evidence of Sex Differences.

Authors:  Ashley C Knight; Cassis Varlow; Junchao Tong; Neil Vasdev
Journal:  ACS Pharmacol Transl Sci       Date:  2021-07-20

Review 3.  Positron Emission Tomography in Animal Models of Tauopathies.

Authors:  Lei Cao; Yanyan Kong; Bin Ji; Yutong Ren; Yihui Guan; Ruiqing Ni
Journal:  Front Aging Neurosci       Date:  2022-01-10       Impact factor: 5.750

Review 4.  Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.

Authors:  Sara Melisa Arciniegas Ruiz; Hagit Eldar-Finkelman
Journal:  Front Mol Neurosci       Date:  2022-01-21       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.